Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest prnewswire.com · 1 day ago

ALLEGIANT TRAVEL COMPANYSECOND QUARTER 2026 FINANCIAL RESULTS*

Second quarter 2026 GAAP loss per share of $(0.21) (1) Second quarter 2026 adjusted diluted earnings per share of $2.19 (2)(3)(4) , up 78.0 percent year-over-year * Second quarter results include the financial performance of Sun Country only from and after the date the acquisition closed on May 13, 2026 LAS VEGAS., Aug. 4, 2026 /PRNewswire/ -- Allegiant Travel Company (NASDAQ: ALGT) today reported the below financial results for second quarter 2026, as well as comparisons to the prior year.

Press releases

More recent coverage

Page 80
ATOM prnewswire.com · 1 day ago

Atomera Provides Second Quarter 2026 Results

LOS GATOS, Calif., Aug. 4, 2026 /PRNewswire/ -- ­­ Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2026.

RRR prnewswire.com · 1 day ago

Red Rock Resorts Announces Second Quarter 2026 Results

LAS VEGAS, Aug. 4, 2026 /PRNewswire/ -- Red Rock Resorts, Inc. ("Red Rock Resorts," "we" or the "Company") (NASDAQ: RRR) today reported financial results for the second quarter ended June 30, 2026. Second Quarter Results Consolidated Operations Net revenues were $510.3 million for the second quarter of 2026, a decrease of 3.0%, or $16.0 million, from $526.3 million in the same period of 2025.

WYNN prnewswire.com · 1 day ago

Wynn Resorts, Limited Reports Second Quarter 2026 Results

LAS VEGAS, August 4, 2026 /PRNewswire/ -- Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the second quarter ended June 30, 2026. Operating revenues were $1.86 billion for the second quarter of 2026, an increase of $119.1 million from $1.74 billion for the second quarter of 2025.

RYTM globenewswire.com · 1 day ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences.

MIST globenewswire.com · 1 day ago

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open.

DRS globenewswire.com · 1 day ago

Leonardo DRS Signs Agreement for New Brookfield, Connecticut, Facility to Support Growth of Naval Power Systems Business

ARLINGTON, Va., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Leonardo DRS, Inc. (Nasdaq: DRS) announced today that it has signed an agreement for a new facility in Brookfield, Connecticut, that will expand and consolidate operations for its Naval Power Systems business, strengthening increased throughput and support for critical U.S. Navy programs and positioning the company for future growth across the evolving nuclear energy landscape.

PCRX globenewswire.com · 1 day ago

Pacira BioSciences Reports Second Quarter 2026 Financial Results

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.

SNFCA globenewswire.com · 1 day ago

Security National Financial Corporation Announces 2026 Q2 Earnings Call

SALT LAKE CITY, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Security National Financial Corporation (NASDAQ: SNFCA) announces that on August 13, 2026, it will hold an earnings call to highlight its 2nd quarter earnings. The 30-minute call will commence at approximately 1PM (MDT) on August 13th and will include a review of its quarterly results as well as an update from the Company's three business segments.

FLYW globenewswire.com · 1 day ago

Flywire Reports Second Quarter 2026 Financial Results

Second Quarter Revenue Increased 27.2% Year-over-Year Second Quarter Revenue Less Ancillary Services Increased 28.5% Year-over-Year Previous Fiscal Year 2026 FX-Neutral Revenue Less Ancillary Services growth guidance raised by 300 bps at midpoint, Adjusted EBITDA margin growth guidance raised by 25 bps at midpoint BOSTON, MA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”), a global payments enablement and software company, today reported financial results for its second quarter ended June 30, 2026. “Q2 was another strong quarter for Flywire, with results ahead of expectations and momentum building across all four verticals.

CSWC globenewswire.com · 1 day ago

Capital Southwest Urges Shareholders to Support Authorized Shares Proposal

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC) today encourages shareholders who have not yet voted to support the Company's proposal to increase the number of authorized shares of common stock. The Company has received substantial shareholder support for the proposal to date.

SPRO globenewswire.com · 1 day ago

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close.

SKWD globenewswire.com · 1 day ago

Skyward Group Reports Second Quarter 2026 Results

HOUSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Group” or the “Company”) today reported second quarter 2026 results. Summary Financial Data               ($ in thousands, except per share amounts) Three months ended June 30,   Six months ended June 30, unaudited 2026   2025(1)   2026   2025(1) Managed Premiums $ 1,058,675     $ 900,849     $ 2,026,384     $ 1,710,234   Gross written premiums(2) $ 740,554     $ 653,861     $ 1,408,258     $ 1,248,431   Fee generating gross written premiums(2) $ 318,121     $ 246,988     $ 618,126     $ 461,803   Net written premiums $ 485,616     $ 339,213     $ 918,499     $ 682,484   Net income $ 49,038     $ 38,839     $ 98,769     $ 80,897   Net operating income(3) $ 59,198     $ 37,496     $ 116,091     $ 75,233   Basic earnings per share $ 1.10     $ 0.96     $ 2.22     $ 2.01   Diluted operating earnings per share $ 1.30     $ 0.89     $ 2.55     $ 1.78   Annualized ROE (4)   15.7 %     17.7 %     17.3 %     19.1 % Annualized operating ROE (5)   19.0 %     17.1 %     20.4 %     17.8 % (1) Select second quarter 2025 metrics for the Skyward Group and Apollo are presented on a pro forma basis for comparative purposes only and are not necessarily indicative of the operating results that Skyward Group would have recognized had the acquisition actually been completed on January 1, 2025.

TWST businesswire.com · 1 day ago

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.

SNDX globenewswire.com · 1 day ago

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million – – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the second quarter ended June 30, 2026, and provided a business update.

SLRC globenewswire.com · 1 day ago

SLR Investment Corp. Announces Quarter Ended June 30, 2026 Financial Results

Net Investment Income of $0.33 Per Share for Q2 2026; Declared Quarterly Distribution of $0.31 Per Share NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company”, “SLRC”, “we”, “us”, or “our”) today reported net investment income (“NII”) of $17.8 million, or $0.33 per share, for the second quarter of 2026. On August 4, 2026, the Board declared a quarterly distribution of $0.31 per share payable on September 25, 2026, to holders of record as of September 11, 2026.

CHEF globenewswire.com · 1 day ago

The Chefs' Warehouse, Inc. Commences Refinancing Process

RIDGEFIELD, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Chefs' Warehouse, Inc. (NASDAQ:CHEF), ("the Company" or “Chefs”) a premier distributor of specialty food products in the United States, the Middle East, and Canada announced today that it commenced a refinancing process with the marketing of a new $625 million term loan facility, subject to market and other considerations.

DNTH globenewswire.com · 1 day ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H'28 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE'26 Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December '26 Building a rheumatology franchise with DNTH212 across our first three prioritized indications of Sjögren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM); Phase 1 healthy volunteer data anticipated by YE'26 Advancing DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases; DNTH312 aims to be Phase 1 ready by YE'27 Approximately $1.2 billion of cash as of June 30, 2026 provides expected runway into 2030 NEW YORK and WALTHAM, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2026, and provided an update on other recent business achievements.

S globenewswire.com · 1 day ago

ConnectWise and SentinelOne Announce Shared Strategy to Advance Managed Cybersecurity for MSPs at Black Hat 2026

Companies align on a long-term vision to more closely connect AI security and autonomous cyber defense with MSP operation platforms while preserving partner choice and human oversight and services Companies align on a long-term vision to more closely connect AI security and autonomous cyber defense with MSP operation platforms while preserving partner choice and human oversight and services

CXDO accessnewswire.com · 1 day ago

Crexendo Announces Strong Second Quarter 2026 Results

PHOENIX, AZ / ACCESS Newswire / August 4, 2026 / Crexendo, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communications as a service (UCaaS) offerings, including voice, video, contact center, and managed IT services tailored to businesses of all sizes, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Financial highlights: Total revenue increased 49% year-over-year to $24.6 million GAAP net income of $1.1 million, or $0.03 per basic and diluted common share.

← Newer
Older →